NRP2 and interstitial lung disease: The proposed mechanism-of-action for this Nrp2 agonist is to promote the differentiation of anti-inflammatory macrophages to downregulate multiple pro-inflammatory cytokines, including TNFα, IL-6, and CCL2, and receptors such as CD14, that are dysregulated in ILD.